The Non-Financial Ledger

Corporate balance sheets track profits and losses in dollars and cents. They have no column for betrayal. There is no line item for a parent’s panic when the very product meant to soothe their child’s irritated skin makes it worse. There is no accounting for the pain of walking on feet that are red, raw, and bleeding because you trusted a label. This is the real cost, the human debt that Unilever’s marketing department refuses to acknowledge.

Consider Renetta Vicks of Rochester, New York. She bought Vaseline Baby Healing Jelly for her son, seeking relief for his eczema. She saw the word “Hypoallergenic” on the jar and believed it. It was a promise of safety, of gentle care. Instead, that promise curdled into a nightmare. The product didn’t help. It prolonged the duration of the skin condition and exacerbated his symptoms by causing his skin to turn red and break out. Imagine the helplessness of applying a “healing” jelly, only to watch your child’s suffering increase. This isn’t just a product failure; it’s a violation of a sacred trust between a caregiver and a corporation that holds itself out as an expert in family care.

Then there is Kari Proskin of Pittsfield, Massachusetts. For over a year, from the winter of 2023 to the spring of 2025, she purchased the same product for her own dry, sensitive skin. She chose it for the same reason: the “Hypoallergenic” claim. The result was not relief but injury. Her use of the product caused her feet to turn red, peel, and bleed, resulting in pain during activities such as walking. The simple act of moving became painful, a direct consequence of using a product marketed as pure and gentle. Once she stopped using Unilever’s product, her feet began to heal. The cause and effect were brutally clear. Unilever sold her a problem masquerading as a solution.

“Plaintiff Proskin’s use of the Product ultimately caused her feet to turn red, peel, and bleed, resulting in pain during activities such as walking.”

These are not isolated incidents. The lawsuit cites countless online consumer reviews echoing the same story of shock and betrayal. Consumers bemoaning the strong fragrance in a product for babies, consumers detailing the rashes and irritation that followed use. The pain documented in this ledger is compounded by the deception. People were not just sold a faulty product; they were sold a lie. They paid a premium for a word, “Hypoallergenic,” believing it was a shield against harm. Instead, Unilever used that word as a weapon to extract more money for a product that was, in reality, more dangerous than its own standard, non-baby-branded alternative.

The trauma of allergic contact dermatitis is insidious. It undermines your confidence and can make you avoid public life. The constant itching, scaling, and cracking skin is a physical burden and a psychological one. When the cause is a product you brought into your home, a product you trusted for your child, the sense of violation is profound. Unilever’s ledger is balanced in boardrooms with profits from this deception. The non-financial ledger, the one that measures human suffering, is deeply, unforgivably in the red.

Societal Impact Mapping

Public Health

Unilever’s alleged deception is a direct assault on public health, exploiting a genuine and growing crisis of skin sensitivity. According to the complaint, which cites the CDC, 14.2% of children aged 0-4 suffered from a skin allergy in 2012, and the prevalence of dermatitis from personal care products has increased by almost 300% between 1996 and 2016. These are not just numbers; they represent millions of children and adults living with painful, persistent skin conditions.

Into this vulnerable market, Unilever pushed a product labeled “Hypoallergenic” that contains one of the most common triggers of allergic reactions: fragrance. The American Academy of Dermatology identifies fragrance as a leading cause of allergic contact dermatitis, affecting an estimated 2.5 million Americans. By including this known sensitizer, Unilever’s product does not reduce the likelihood of an allergic reaction; it actively increases it for a significant portion of its intended user base—babies and people with sensitive skin. The complaint states the product is “just as likely and, for some products, more likely to cause an allergic reaction” than competitors who make no such claims. This is a betrayal of the public trust and an act of corporate negligence that creates, rather than alleviates, suffering.

Economic Inequality

The “hypoallergenic” label is a tool for price discrimination, used to extract wealth from concerned consumers and families. Unilever knowingly charges a premium for the Vaseline Baby product, leveraging the perception of safety and purity that the label implies. The lawsuit provides damning evidence of this. The average price per ounce of Unilever’s product ranges from $0.42 to $1.09, and can be found for as high as $2.75. In one specific example from November 2025, a 2.89 oz tube was priced between $4.13 and $10.50.

This pricing stands in stark contrast to genuinely hypoallergenic store-brand alternatives. Walmart’s Equate Baby Petroleum Jelly, which contains no fragrance, costs around $0.18 – $0.20 per ounce. Target’s Up & Up version, also fragrance-free, costs about $0.32 per ounce. This means consumers are often paying double, triple, or even more for a product that isn’t only falsely advertised because that wouldn’t be evil enough, but it’s also demonstrably inferior and more dangerous than its cheaper counterparts on top of that. This is a direct tax on parental fear and a mechanism for transferring money from the pockets of working families to Unilever’s corporate coffers, all based on a single misleading word.

Environmental Degradation

The source document, a legal complaint focused on consumer harm and false advertising (Case 2:25-cv-17887-SDW-JSA), does not contain specific information regarding the environmental impact of the manufacturing, packaging, or disposal of Unilever’s Vaseline Baby Healing Jelly. The core of the legal action is centered on public health and economic deception.

Legal Receipts

The following are direct statements and facts taken from the class action complaint filed in the United States District Court for the District of New Jersey (Case No. 2:25-cv-17887-SDW-JSA). These are not our opinions; they are the allegations laid out in the legal challenge against Unilever United States, Inc.

This class action seeks to hold Defendant Unilever United States, Inc. accountable for falsely labeling and marketing its Vaseline brand Baby Healing Jelly (the “Product”) as “hypoallergenic.”

Nature of Action, ¶ 1

The truth is the Product is not hypoallergenic because it contains fragrance chemicals in amounts that can reasonably be expected to induce an allergic response in a significant number of the Product’s intended users (i.e., individuals with sensitive skin, or with children who have sensitive skin).

Nature of Action, ¶ 6

Indeed, fragrance is one of the most common allergens and skin irritants, and a leading cause of allergic contact dermatitis according to the American Academy of Dermatology (“AAD”). The AAD estimates about 2.5 million Americans have fragrance allergies.

Nature of Action, ¶ 6

Plaintiff Vicks purchased the Product to help treat her son’s eczema. However, the Product failed to relieve symptoms of eczema and, in fact, prolonged the duration of the skin condition and exacerbated his symptoms by causing his skin to turn red and break out.

Parties, ¶ 11

Plaintiff Proskin’s use of the Product ultimately caused her feet to turn red, peel, and bleed, resulting in pain during activities such as walking. … Once she ceased using the Product, the condition of her feet improved.

Parties, ¶ 14

By deceiving consumers about the nature, quality, and/or ingredients of its Product, Defendant was and continues to take away market share from competing products and command a price premium, thereby increasing its own sales and profits.

Factual Allegations, ¶ 78

The Product is also far more likely to cause an allergic reaction in its intended users than similar, competing products which claim to be hypoallergenic on their labels and, in fact, are hypoallergenic… An example is Walmart’s Equate Baby Petroleum Jelly, which has a “Hypoallergenic” claim on its front label… and contains zero fragrance chemicals or other skin sensitizers.

Nature of Action, ¶ 8

What Now?

Accountability for this kind of public deception doesn’t end with a lawsuit. Real change requires sustained pressure on the corporations responsible and the regulatory bodies that enable them. The individuals who signed off on this marketing strategy must be held to account.

The Resistance

This fight is bigger than one product. It’s about demanding corporations stop profiting from our pain and our trust. Corporate legal teams are designed to wait us out, to bury us in paperwork until we give up. We cannot let them.

• Support Local Organizing: Connect with local consumer protection groups. Share this information. Collective action is the only language these giants understand.
• Practice Mutual Aid: Share information about safe, truly hypoallergenic, and affordable alternatives within your community. Create networks of care that bypass predatory corporate marketing.
• Demand Regulatory Action: The FDA has failed to define or regulate the term “hypoallergenic,” creating a wild west where corporations can make baseless claims without consequence. Demand they do their job.